AtriCure, Inc. (ATRC) Insider Trading

Last 12 months

Insiders sold $4.37M and bought nothing on the open market.

20% of the selling was scheduled in advance under 10b5-1 plans. Director Sven Wehrwein sold $946k on Jul 28, 38% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2024.

Net open-market

−$4.37M

0 buys · 16 sales

Under a 10b5-1 plan

20%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

May 2024

May 30, 2024

Get an email when ATRC's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 23	Salvatore Privitera Chief Technical Officer	Sold10b5-1 plan	4,519	$60.00	$271k	3.1%	Form 4
Sep 11	Regina E Groves Director	SoldNo plan	5,313	$54.22	$288k	13%	Form 4
Sep 8	Salvatore Privitera Chief Technical Officer	Sold10b5-1 plan	3,657	$55.00	$201k	2.4%	Form 4
Sep 2	Salvatore Privitera Chief Technical Officer	Sold10b5-1 plan	7,763	$52.50	$408k	4.9%	Form 4
Aug 24	Karl S. Dahlquist Chief Legal Officer	SoldNo plan	9,370	$48.89	$458k	9.7%	Form 4
Aug 5	Maggie Yuen Director	SoldNo plan	3,500	$38.42	$134k	20%	Form 4
Aug 5	Karen Prange Director	SoldNo plan	3,564	$38.80	$138k	14%	Form 4
Jul 29	Justin J Noznesky Chief Mktg & Strategy Officer	SoldNo plan	6,182	$38.80	$240k	5.8%	Form 4
Jul 28	Vinayak Doraiswamy Chief Scientific Officer	SoldNo plan	6,000	$38.88	$233k	6.5%	Form 4
Jul 28	Sven Wehrwein Director	SoldNo plan	25,000	$37.84	$946k	38%	Form 4
May 20	Karen Prange Director	SoldNo plan	3,000	$28.65	$86k	10%	Form 4
May 15	Vinayak Doraiswamy Chief Scientific Officer	SoldNo plan	5,000	$28.13	$141k	5.2%	Form 4
Mar 12	Vinayak Doraiswamy Chief Scientific Officer	SoldNo plan	5,000	$29.83	$149k	4.9%	Form 4
Nov 26, 2025	Justin J Noznesky Chief Mktg & Strategy Officer	SoldNo plan	5,166	$37.29	$193k	6.2%	Form 4
Nov 24, 2025 – Nov 25, 2025	Sven Wehrwein Director	SoldNo plan 2 parts	10,000	$37.66 average	$377k	23%	Form 4
Nov 21, 2025	Maggie Yuen Director	SoldNo plan	3,000	$35.72	$107k	21%	Form 4
Sep 12, 2025	Justin J Noznesky Chief Mktg & Strategy Officer	SoldNo plan	3,000	$36.30	$109k	3.4%	Form 4
Aug 22, 2025	Sven Wehrwein Director	SoldNo plan	5,000	$37.00	$185k	13%	Form 4
Aug 19, 2025	Sven Wehrwein Director	SoldNo plan	5,000	$36.00	$180k	13%	Form 4
Aug 6, 2025	Regina E Groves Director	SoldNo plan	2,452	$36.82	$90k	6.8%	Form 4
Aug 5, 2025	Vinayak Doraiswamy Chief Scientific Officer	SoldNo plan	2,500	$36.58	$91k	3.4%	Form 4
May 28, 2025	Vinayak Doraiswamy Chief Scientific Officer	SoldNo plan	2,500	$33.44	$84k	3.3%	Form 4
Mar 5, 2025	Karen Prange Director	SoldNo plan	6,100	$38.12	$233k	25%	Form 4

Sep 2310b5-1 plan
Salvatore Privitera
Chief Technical Officer · sold 4,519 at $60.00
$271k
3.1% of stake
Sep 11No plan
Regina E Groves
Director · sold 5,313 at $54.22
$288k
13% of stake
Sep 810b5-1 plan
Salvatore Privitera
Chief Technical Officer · sold 3,657 at $55.00
$201k
2.4% of stake
Sep 210b5-1 plan
Salvatore Privitera
Chief Technical Officer · sold 7,763 at $52.50
$408k
4.9% of stake
Aug 24No plan
Karl S. Dahlquist
Chief Legal Officer · sold 9,370 at $48.89
$458k
9.7% of stake
Aug 5No plan
Maggie Yuen
Director · sold 3,500 at $38.42
$134k
20% of stake
Aug 5No plan
Karen Prange
Director · sold 3,564 at $38.80
$138k
14% of stake
Jul 29No plan
Justin J Noznesky
Chief Mktg & Strategy Officer · sold 6,182 at $38.80
$240k
5.8% of stake
Jul 28No plan
Vinayak Doraiswamy
Chief Scientific Officer · sold 6,000 at $38.88
$233k
6.5% of stake
Jul 28No plan
Sven Wehrwein
Director · sold 25,000 at $37.84
$946k
38% of stake
May 20No plan
Karen Prange
Director · sold 3,000 at $28.65
$86k
10% of stake
May 15No plan
Vinayak Doraiswamy
Chief Scientific Officer · sold 5,000 at $28.13
$141k
5.2% of stake
Mar 12No plan
Vinayak Doraiswamy
Chief Scientific Officer · sold 5,000 at $29.83
$149k
4.9% of stake
Nov 26, 2025No plan
Justin J Noznesky
Chief Mktg & Strategy Officer · sold 5,166 at $37.29
$193k
6.2% of stake
Nov 24, 2025 – Nov 25, 2025No plan
Sven Wehrwein
Director · sold 10,000 at avg $37.66
$377k
23% of stake
Nov 21, 2025No plan
Maggie Yuen
Director · sold 3,000 at $35.72
$107k
21% of stake
Sep 12, 2025No plan
Justin J Noznesky
Chief Mktg & Strategy Officer · sold 3,000 at $36.30
$109k
3.4% of stake
Aug 22, 2025No plan
Sven Wehrwein
Director · sold 5,000 at $37.00
$185k
13% of stake
Aug 19, 2025No plan
Sven Wehrwein
Director · sold 5,000 at $36.00
$180k
13% of stake
Aug 6, 2025No plan
Regina E Groves
Director · sold 2,452 at $36.82
$90k
6.8% of stake
Aug 5, 2025No plan
Vinayak Doraiswamy
Chief Scientific Officer · sold 2,500 at $36.58
$91k
3.4% of stake
May 28, 2025No plan
Vinayak Doraiswamy
Chief Scientific Officer · sold 2,500 at $33.44
$84k
3.3% of stake
Mar 5, 2025No plan
Karen Prange
Director · sold 6,100 at $38.12
$233k
25% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ATRC, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

BVSBioventus Inc.

GKOSGlaukos Corporation

UFPTUFP Technologies Inc.

AORTArtivion Inc.

NVCRNovoCure Ltd.

ARAYAccuray Incorporated

MDXGMiMedx Group, Inc.

ATECAlphatec Holdings Inc.

Spot a number that looks wrong? Check it in ATRC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ATRC

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.